EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships

Siew Lee Cheong, Gopalakrishnan Venkatesan, Priyankar Paira, Ramasamy Jothibasu, Alexander Laurence Mandel, Stephanie Federico, Giampiero Spalluto, Giorgia Pastorin

International Journal of Medicinal Chemistry · 2011

DOI: 10.1155/2011/480652 ↗
AbstractBibliografische Angaben

Abstract

In the past few decades, medicinal chemistry research towards potent and selective antagonists of human adenosine receptors (namely, A 1 , A 2A , A 2B , and A 3 ) has been evolving rapidly. These antagonists are deemed therapeutically beneficial in several pathological conditions including neurological and renal disorders, cancer, inflammation, and glaucoma. Up to this point, many classes of compounds have been successfully synthesized and identified as potent human adenosine receptor antagonists. In this paper, an overview of the structure-activity relationship (SAR) profiles of promising nonxanthine pyrazolo derivatives is reported and discussed. We have emphasized the SAR for some representative structures such as pyrazolo-[4,3- e ]-1,2,4-triazolo-[1,5- c ]pyrimidines; pyrazolo-[3,4- c ] or -[4,3- c ]quinolines; pyrazolo-[4,3- d ]pyrimidinones; pyrazolo-[3,4- d ]pyrimidines and pyrazolo-[1,5- a ]pyridines. This overview not only clarifies the structural requirements deemed essential for affinity towards individual adenosine receptor subtypes, but it also sheds light on the rational design and optimization of existing structural templates to allow us to conceive new, more potent adenosine receptor antagonists.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →